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Abstract
Objectives A small subset of patients treated with immune checkpoint inhibitors manifest atypical patterns of response, the 
so-called pseudoprogression (PP) and hyperprogression (HP). Their prevalence in urothelial (UC) and renal cancer (RCC) 
remains, to date, mostly uninvestigated. Therefore, we aimed to provide a summary of the current knowledge about PP and 
HP during immune checkpoint inhibitor therapy in UC and RCC patients.
Methods and materials A systematic medline/pubmed© literature search was performed. The atypical patterns of response 
to systemic immunotherapy were reviewed. Endpoints were PP and HP in UC and RCC.
Results Tumors respond differently to immunotherapy compared to systemic chemotherapy. To evaluate response to immu-
notherapy, new guidelines (iRECIST) have been developed. To date, no studies focused on PP in UC and RCC, and the only 
way to evaluate its role is to take patients who respond to treatment beyond progression as surrogate for pseudoprogressors. 
PP seems to occur in a non-negligible rate of UC and RCC (from 1.5 to 17% and from 5 to 15%, respectively). The concept 
of HP, defined as a rapid progression after treatment, just took the first steps, and therefore, data from ongoing trials are 
awaited to elucidate its impact in genitourinary cancers.
Conclusions PP and HP are not uncommon entities in UC and RCC patients, treated with PD-1/PD-L1 inhibitors. Further 
investigation is warranted to define which patients are likely to experience PP and could benefit from treatment beyond pro-
gression and which ones will instead rapidly experience progression despite treatment and should, therefore, avoid systemic 
immunotherapy.
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Introduction
Over the last 5 years, immunotherapy has come to the fore-
front of cancer therapy, promising to change the treatment 
paradigms of advanced tumors. In the urologic context, the 
recent approval of multiple programmed death receptor-1 
(PD-1) axis inhibitors is continuously transforming the treat-
ment of advanced urothelial (UC) and renal cell carcinoma 
(RCC) [1], awakening hope where there was none.
At the same time, this represents a great challenge to 
physicians facing agents with novel mechanisms of action 
that differs from conventional chemotherapy and is unique 
in related side effects and patterns of response. One of the 
major challenges is actually the appropriate assessment of 
treatment response. It is known that tumors respond dif-
ferently to immunotherapy compared to systemic chemo-
therapy and usage of traditional response evaluation criteria 
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for solid tumor (RECIST) could result in tumor response 
misclassification [2].
A small subset of patients treated with immune check-
point inhibitors manifest atypical patterns of response, the 
so-called pseudoprogression (PP) and hyperprogression 
(HP). The first, also known as tumor flare, is characterized 
by a transient increase followed by a decrease in total tumor 
burden [3]. HP instead is defined as a rapid increase in tumor 
growth rate (minimum twofold) compared to the expected 
growth rate [4]. These atypical patterns of response have 
been also reported for advanced UC and RCC, mainly as 
case reports in the context of phase II–III trials.
Understanding and identifying PP and HP is of funda-
mental importance for uro-oncologists to improve treat-
ment decisions and patients’ outcomes. These phenomena 
are likely to be different from one malignancy to the others 
in addition to individual differences.
We sought, therefore, to review the literature to provide 
a summary of the current knowledge about PP and HP dur-
ing immune checkpoint inhibitor therapy in UC and RCC 
patients.
Methods and materials
A systematic medline/pubmed© literature search was per-
formed with different combinations of terms as “pseudo-
progression”, “hyperprogression”, “response”, “radiologi-
cal response”, “treatment beyond progression”, “bladder 
cancer”, “urothelial cancer” and “renal cancer”. Moreover, 
all the published RCTs enrolling patients with either UC 
or RCC were reviewed for the purpose of this article. No 
time period restriction was set. Original articles, reviews and 
editorials were selected based on their clinical relevance. 
Cited references from selected articles were analyzed to find 
and include significant papers missed from our search. The 
atypical patterns of response to systemic immunotherapy 
were reviewed. End points were PP and HP in UC and RCC.
Summary of evidence
How to evaluate the response to systemic 
immunotherapy
Immunotherapy does not exhibit the same patterns of 
response in comparison to traditional chemotherapy. Using 
assessment tools that have been developed and evaluated for 
conventional chemotherapy can result in inaccurate interpre-
tation of the response, premature termination of therapy and 
unnecessary removal of patients from clinical trials, depriv-
ing them from a potentially life-extending treatment.
Historically, the World Health Organization (WHO) and 
the RECIST group have developed response criteria for solid 
tumors treated with systemic chemotherapy to standard-
ize the characterization of treatment efficacy and to allow 
comparison between trials and with historical data [5, 6]. 
RECIST guidelines have been revised and a new version 
(RECIST 1.1) was published in 2009. Based on these rec-
ommendations, an early increase in tumor growth and/or 
the appearance of new lesions after therapy are considered 
as tumor progression and indicate the need for treatment 
cessation [7].
However, both WHO and RECIST 1.1 criteria have 
proven to be inadequate for the assessment of response to 
immunotherapy agents such as immune checkpoint inhibi-
tors, partly because of the time needed to mount an anti-
tumor immune response, and partly because of the possi-
ble occurrence of atypical patterns of response in subjects 
treated with immunotherapy.
In 2009, the immune-related response criteria (irRC) were 
proposed to specifically assess tumor response to immune 
checkpoint inhibitors with two main innovations: new or 
enlarged lesions should be incorporated into total tumor vol-
ume rather than immediately taken as indicator of disease 
progression; designation of disease progression requires an 
increase in tumor volume that has to be confirmed in two 
consecutive imaging studies at least 4 weeks apart [8].
In early 2017, RECIST working group developed a guide-
line of a modified RECIST 1.1 for immune-based therapeu-
tics (iRECIST) [2]. Patterns of response based on iRECIST 
criteria include complete response (total remission of all 
target and non-target lesions, including the lack of appear-
ance of new lesions; to be confirmed no less than 4 weeks 
after the first assessment); partial response (a decrease of at 
least 50% in the total tumor burden compared to baseline; 
to be confirmed after at least 4 weeks); stable disease (the 
change of the total tumor burden is reduced of less than 
50% when compared with baseline or increased less than 
20% compared to nadir); unconfirmed progressive disease 
(increase in the total tumor burden of at least 20% com-
pared to nadir; further confirmation at imaging is needed to 
rule out PP); progressive disease (increase in the total tumor 
burden of at least 20% when compared to nadir confirmed 
by a further progression after 4–8 weeks) [9]. This update 
incorporates the suggestion of performing biopsies of target 
lesions whenever possible before the designation of relapse 
to rule out the presence of an immune infiltrate. In case of 
unfeasible biopsy, a follow-up scan should be performed to 
confirm relapse in all clinically stable patients. However, 
so far no clinical trials have incorporated biopsies of target 
lesions as part of their protocols.
Similar to RECIST 1.1 and irRC, also with iRECIST, 
treatment response evaluation could be done with almost 
all current imaging modalities including CT, MR and PET/
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CT. However, the measurements performed with iRECIST 
criteria seem to be more reproducible compared to the bidi-
mensional approach used for irRC [9, 10].
Atypical pattern of response and progression 
to systemic immunotherapy
With the widespread implementation of immunotherapy in 
the treatment paradigm of several malignancies, clinicians 
are facing a major challenge in the evaluation of treatment 
response. Recently, with the advent of immunotherapy, new 
response and progression patterns have been reported. Wol-
chock et al. [8] first provided a description of response pat-
terns to systemic immunotherapy in patients with melanoma.
Pseudoprogression was first described in three patients 
with metastatic, unresectable melanoma treated with ipili-
mumab, a human anti-CTLA-4 monoclonal antibody [11]. 
These patients experienced an initial increased size of tumor 
lesions, with subsequent tumor burden and durable response. 
The histopathology of lesion biopsies confirmed the absence 
of tumor with the presence of inflammatory infiltrate or 
necrosis. Actually, it seems that PP is connected with infil-
trations of active T cells and other immune cells within 
the lesion. According to immune-related response criteria 
(irRC), Hodi et al. [12] found that 12% of melanoma patients 
treated with pembrolizumab experienced PP before clini-
cal and radiological responses. This atypical response was 
then confirmed to be present in several other solid tumors 
treated with PD-1 and PD-L1 inhibitors such as bladder, 
breast, colorectal, esophageal, gastric, head and neck, lung, 
pancreatoduodenal, ovarian, renal cell, sarcoma, and uterine 
cancer [13]. A systematic review of 38 studies found a 6% 
rate of atypical responses (151 of 2400 patients with solid 
tumors treated with anti-PD-1 therapy) [14].
Accurate identification of PP is of meaningful importance 
in decision making for treatment continuation. Moreover, 
its occurrence, together with a potential delayed effect of 
immunotherapeutic drugs, could account for the oncological 
results obtained in certain patients with the so-called “treat-
ment beyond progression”, which is today allowed in clinical 
trials when specific criteria such as acceptable performance 
status, no impending end organ damage and no ongoing or 
serious toxic effects are met. Finally, PP seems to be associ-
ated with better overall survival (OS) rates (high likelihood 
of > 1 year survival) compared to patients experiencing pro-
gressive disease, stable response or partial response [15].
On the other hand, a new pattern of progression has been 
recently reported. It has been called HP and concerns a rapid 
disease progression under immunotherapeutic agents. Cham-
piat et al., in a study of 218 patients with solid tumors or 
lymphoma treated either with PD-1/PD-L1 inhibitors, first 
reported the presence of hyperprogressive features in 12 
(6%) immunotherapy-treated patients [4]. HP was defined as 
twofold increase of the expected tumor growth rate (which 
is an estimation of the increase in tumor volume over time) 
in patients with disease progression; it was associated with 
advanced age at treatment and worse oncological outcomes 
such as median overall survival (OS). Kato et al. [16] inves-
tigated the presence of potential genomic markers associated 
with HP in 155 patients with stage IV solid tumors treated 
in clinical trials with CTLA-4, PD-1/PD-L1 inhibitors or 
other investigation immunotherapeutic agents. Patients who 
suffered from HP harbored EGFR or MDM2/4 alterations, 
suggesting particular caution in treating patients with these 
genomic profiles.
However, the concept of HP is still unrefined suffering 
from limitations such as the low number of patients inves-
tigated, the use of unvalidated criteria to define patients 
who experience HP and the apparent absence of underlying 
mechanisms, difficult to understand in the absence of biopsy 
specimens from hyperprogressive lesions [17]. Therefore, 
data from ongoing trials are awaited to confirm this prelimi-
nary hypothesis, and in case, to solve this issue as quickly 
as possible.
Pseudoprogression in urothelial cancer
The frequency and clinical impact of PP in UC is almost 
uninvestigated. However, evaluating the number of patients 
who experience delayed response after treatment, the rate 
of PP seems to be lower if compared to other solid tumor 
patients. To date, no studies focused on PP and the only way 
to evaluate its role in urothelial cancers is to take patients 
which respond to treatment beyond progression as surrogate 
for pseudoprogressors (Table 1).
In the IMvigor210 phase II trial, locally advanced and 
metastatic urothelial cancer patients who have progressed 
following treatment with platinum-based chemotherapy were 
treated with atezolizumab [18]. Overall, 121 of 310 patients 
were treated beyond progression and 20 (6%) of them expe-
rienced a delayed response (defined as subsequent ≥ 30% 
decrease in volume lesion from baseline) despite initial radi-
ological progression. Previously, Powles et al. [19] reported 
a PP rate of 1.5% in patients treated with atezolizumab.
Atypical patterns of response have been seen also in 
patients resistant to platinum-based chemotherapy who 
received nivolumab. In the phase I–II CheckMate 032 trial, 
nine patients (12%) experienced delayed response after ini-
tial progression [20]. Similarly, of 265 patients who received 
nivolumab in the CheckMate 275 study [21], 70 (26%) were 
treated beyond progression and 24 (9%) experienced non-
conventional benefits. Non-conventional benefiter patients 
had to meet one of the following criteria: appearance of a 
new lesion followed by decrease from baseline of at least 
10% in the sum of the target lesions; initial increase of the 
target lesions followed by reduction from baseline of at least 
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30%; initial increase of the target lesions followed by at least 
two tumor assessments showing no further progression. 
Unfortunately, the survival data of patients experiencing 
non-conventional patterns of response in these trials are, to 
date, not available.
Finally, no data about PP in patients with metastatic 
urothelial cancer treated either with pembrolizumab, ave-
lumab or durvalumab are reported so far.
Pseudoprogression in renal cancer
Although RCC has been treated with immunomodulating 
agents such as cytokines for nearly 40 years, the imaging 
patterns and features of response to the new anti-PD-1/
PD-L1 agents need further characterization. No study specif-
ically focusing on atypical patterns of response in renal can-
cer have been published so far. Moreover, biopsies of target 
lesions were not performed in any of the trials investigating 
the effect of immunotherapeutic agents in metastatic RCC 
(mRCC). Therefore, the occurrence of PP in RCC could only 
be estimated by evaluating the proportion of patients treated 
beyond progression who experienced a sustained reduction 
and/or stabilization in the size of target lesions despite initial 
progression (Table 2).
Within a phase I study, Brahmer et al. first reported the 
case of a 72-year-old with multiorgan mRCC who experi-
enced an atypical response after one cycle of nivolumab; 
progression in a pancreatic metastasis but regression in 
other sites. This evolved to an overall partial response 
after two additional cycles, lasting over 16 months with-
out further therapy [22]. In an analog phase I, dose-esca-
lation study of 296 patients with solid tumors, a total of 
eight patients (3%) with melanoma, lung cancer, or RCC, 
experienced PP [23]. In the related cohort expansion 
study of 34 mRCC patients, up to 29% (n = 9) of objec-
tive responses, as per RECIST criteria, were observed. 
Three additional patients (9%) experienced unconven-
tional responses that did not fit RECIST criteria such as 
Table 1  List of studies investigating the treatment beyond progression as surrogate for pseudoprogression after immunotherapy in urothelial 
cancer
Refs. Study design Patients Treatment Num-
ber of 
patients
Evaluation criteria Conven-
tional 
response
Atypical 
response
Rosenberg et al. [16] Phase II Progressing metastatic urothelial 
cancer following platinum-based 
chemotherapy
Atezolizumab 310 RECIST 1.1 45 20
Sharma et al. [18] Phase I/II Progressing metastatic urothelial 
cancer following platinum-based 
chemotherapy
Nivolumab 78 RECIST 1.1 19 9
Sharma et al. [19] Phase II Progressing metastatic urothelial 
cancer following platinum-based 
chemotherapy
Nivolumab 265 RECIST 1.1 52 24
Powles et al. [17] Phase I Progressing metastatic urothe-
lial cancer following systemic 
chemotherapy
MPDL3280A 67 RECIST 1.1 17 1
Table 2  List of studies investigating the treatment beyond progression as surrogate for pseudoprogression after immunotherapy in renal cell car-
cinoma
Refs. Study design Patients Treatment Number of 
patients with 
mRCC 
Evaluation criteria Conven-
tional 
response
Atypical 
response
Brahmer et al. [20] Phase I Metastatic solid tumors 
refractory to systemic treat-
ment
Nivolumab 1 RECIST 1.0 0 1
McDermott et al. [22] Phase I Metastatic renal cell refrac-
tory to systemic treatment
Nivolumab 34 RECIST 1.0 9 3
Motzer et al. [23] Phase II Progressing metastatic renal 
cell carcinoma following 
VEGF inhibitors
Nivolumab 168 RECIST 1.1 35 25
Escudier et al. [24] Phase III Metastatic renal cell refrac-
tory to systemic treatment
Nivolumab 406 RECIST 1.1 90 20
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persistent reduction in target lesions in the presence of 
new lesions or regression after initial progression [24].
Recently, in a randomized phase II trial investigating 
the effect of different nivolumab doses (0.3, 2 or 10 mg/
kg) in mRCC patients previously treated with agents tar-
geting the vascular endothelial growth factor pathway, 36 
patients were treated beyond progression and 25 of them 
(69%) experienced durable response consisting in tumor 
reduction or stabilization [25].
These findings led to the idea that patients treated 
with nivolumab could potentially benefit from treatment 
beyond progression. Based on this hypothesis, Escudier 
et al. [26] investigated the clinical benefit of treatment 
beyond progression in the context of the phase III Check-
Mate 025 study (NCT01668784). Of the entire cohort of 
406 enrolled patients, 316 (78%) progressed and 153 of 
these (48%) were treated beyond progression. The choice 
of continuing treatment despite progression was based on 
patients’ and tumor’s characteristics such as good perfor-
mance status, short time to progression, low incidence of 
new bone lesions and improved quality of life. An objec-
tive response, defined as ≥ 30% of tumor burden reduc-
tion, was observed in 20 (13%) patients. To date, there are 
no available data about survival in patients treated beyond 
progression who experienced a subsequent response.
Hyperprogression in urothelial and renal cancer
Hyperprogression is a very poorly investigated phenom-
enon. To our knowledge, only two studies focusing on 
this atypical pattern of response have been published so 
far, and only one trial enrolled patients with UC and RCC 
[4, 27]. Champiat et al. [4], by reviewing the medical 
records of 218 patients with solid tumors treated with 
immunotherapy, aimed to investigate prevalence, natural 
history and predictive factors of HP. Of the 131 evaluable 
patients, 12 (9%) were considered as having HP, defined 
as ≥ twofold increase of the tumor growth rate after anti-
PD-1/PD-L1 therapy. Two out of eight (25%) patients 
with urothelial cancer enrolled in the study experienced 
HP, representing one of the highest proportions among 
all cancer types. On the other hand, no patients with RCC 
were found to rapidly progress after treatment. Older age 
at treatment was found to be associated with a higher risk 
of developing HP.
Despite the low number of patients evaluated and the 
mainly informative nature of the study, this trial points 
out that although immunotherapy represents a break-
through by leading to durable tumor response in some 
cases, a small subset of patients seem to experience a 
tumor flare after treatment, leading inevitably to death.
Conclusions
Till now, the occurrence of PP in metastatic UC and RCC 
has been only suggested by evaluating patients treated 
beyond progression who finally experienced sustained 
reduction in tumor burden or stabilization in the size of 
target lesions. However, the efficacy of treatment beyond 
progression could be explained by several factors. First, 
the occurrence of the PP phenomenon; second, the pres-
ence of late responder patients (who require a longer 
period of time on treatment); third, the presence of the 
genetic intratumor heterogeneity that could be involved in 
the case of mixed response (reduction of target lesion in 
the presence of new metastatic deposits).
To our knowledge, biopsies of target lesions in patients 
with metastatic UC and RCC to histologically demonstrate 
the presence of an immune infiltrate have never been per-
formed. Therefore, to better understand the real incidence 
of PP in these patients, future trials should include biop-
sies of target lesions as part of the protocol, as suggested 
by iRECIST guidelines. Moreover, further investigations 
are warranted to better define which patient will respond 
to treatment beyond progression to provide better survival 
outcomes without compromising safety and quality of life, 
which remains one of the main target to pursuit in meta-
static and end-of-life settings.
Hyperprogression remains an almost undiscovered 
entity. Further studies are urgently needed to understand 
why some patients rapidly progress after treatment and 
predicting which patient will experience this undesired 
outcome.
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